Isomorphic Labs

Explore the latest insights on Isomorphic Labs and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Isomorphic Labs’ developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Innogen Licenses Efsubaglutide Alfa to Arcera in Emerging Markets – Deal Worth Over USD 1 Billion

Innogen Pharmaceutical Group Co., Ltd. (HKG: 2591) announced an exclusive license agreement with Arcera Life Sciences Ltd. ("Arcera") to advance the development and commercialization of efsubaglutide alfa, the company's long‑acting…

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.